Replies to post #5734 on Enanta Pharmaceuticals Inc (ENTA)

[DewDiligence]

A third possibility, albeit less likely, is that ENTA sells the RSV program for cash and continues as a pure-play immunology company. BHVN did something similar to this when PFE acquired its migraine program.

[dewophile]

Is it too big of a leap to assume that an RSV partnership may be close given the extended cash runway?

The cash runway apparently does not factor in any partnership for RSV

The other option is that it dies on the vine if nobody is interested and they are done spending money on it

This happened to the covid asset, but there seems like a clear path to market in the adult RSV population, and they would be first to market. Two important distinctions from the covid asset